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Pegﬁlgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related
outcomes in cancer patients in Spain – results of the LEARN Study
Daily granulocyte colony-stimulating factors [(G-CSFs); e.g. ﬁlgrastim, lenograstim] are frequently used to
reduce the duration of chemotherapy-induced neutropenia (CIN) and the incidence of febrile neutropenia (FN)
in cancer patients. A pegylated formulation of ﬁlgrastim, pegﬁlgrastim, which is administered once per cycle,
was introduced in Spain in 2003. LEARN was a multi-centre, retrospective, observational study in Spain
comparing patterns of use of daily G-CSF and pegﬁlgrastim, and CIN-related outcomes in adults with
non-myeloid malignancies receiving myelosuppressive chemotherapy. Outcome measures were the percentage
of patients receiving G-CSF for primary prophylaxis versus secondary prophylaxis/treatment, duration of
treatment with G-CSF and incidence of CIN-related complications. Medical records from consecutive patients
with documented pegﬁlgrastim (n = 75) or daily G-CSF (n = 111) use during 2003 were included. The proportion
of patients receiving primary or secondary prophylaxis was comparable between the pegﬁlgrastim (39 and 48%
respectively) and daily G-CSF (40 and 48% respectively) groups. However, there was a trend towards less
frequent use to treat a neutropenic event such as FN or neutropenia in the pegﬁlgrastim group (17 versus 30%
with daily G-CSF). Chemotherapy-induced neutropenia-related complications were less frequent in patients
receiving pegﬁlgrastim (e.g. FN 11 versus 24% with daily G-CSF). This is the ﬁrst study to show the potential
beneﬁts of pegﬁlgrastim over daily G-CSF in Spanish clinical practice.
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Chemotherapy-induced neutropenia (CIN) is the most
common dose-limiting toxicity of cancer chemotherapy.
Patients receiving myelosuppressive chemotherapy fre-
quently develop severe grade 3 or 4 neutropenia or febrile
neutropenia (FN), which can make them susceptible to
the development of potentially life-threatening infections
(Dale et al. 2001; Aapro et al. 2006; Smith et al. 2006).
Historically, the principal strategies for managing CIN
are reducing the dose intensity and total dose of the che-
motherapy. In the case of FN, a medical emergency, hos-
pitalization is generally required, with the administration
of antibiotics to combat infection. It is, however, well
documented that reducing or delaying the chemotherapy
dose can compromise treatment outcomes and ultimately
patient survival (Bonadonna et al. 1995; Budman et al.
1998). Moreover, use of antibiotics can be lifesaving but
may be associated with adverse effects and the emergence
of resistant pathogens (Yoshida & Ohno 2004).
The introduction of granulocyte colony-stimulating
factors (G-CSFs) over a decade ago has had a signiﬁcant
impact on the management of myelotoxicity associated
with cancer chemotherapy. Daily subcutaneous doses of
G-CSFssuchasﬁlgrastim(Neupogen®,Amgen,Inc.,Thou-
sandOaks,CA,USA)andlenograstim(Granocyte®,Chugai
Sanoﬁ-Aventis, Paris, France) are now commonly used in
clinical practice to reduce the incidence, duration and
severity of CIN, the incidence of FN, and the risk of infec-
tion in patients undergoing myelosuppressive chemo-
therapy (Crawford et al. 1991; Trillet-Lenoir et al. 1993).
Guidelines published by the National Comprehensive
Cancer Network recommend the routine prophylactic use
of CSFs to prevent the development of FN in patients in
whom the risk of developing FN or a neutropenic event
compromising treatment with systemic chemotherapy is
20% or higher (deﬁned as ‘high-risk’ patients) (Crawford
et al. 2005; Lyman 2005). Updated guidelines from the
American Society for Clinical Oncology and from the
European Organization for Research and Treatment of
Cancer also recommend the use of CSFs in patients on
regimens associated with a 20% or greater risk of FN
(Aapro et al. 2006; Smith et al. 2006). Where the risk of FN
is 10–20%, patient-related factors such as age should be
taken into account when deciding whether G-CSFs are
required. Using prophylactic G-CSF support, planned che-
motherapy doses can be administered on time, more fre-
quently and at the desired intensity, thus optimizing the
outcome for the patient (Lyman et al. 2002).
The use of pegylation technology has created a new
molecule, pegﬁlgrastim (Neulasta®, Amgen, Inc.), with a
signiﬁcantly improved pharmacokinetic proﬁle compared
with daily ﬁlgrastim. Pegﬁlgrastim is produced by the
covalent attachment of a 20-kDa polyethylene glycol
moiety to the N-terminal methionine residue of
ﬁlgrastim. Pegylation results in reduced renal clearance of
pegﬁlgrastim compared with ﬁlgrastim, leaving neutro-
phil receptor-mediated clearance as the dominant clear-
ance mechanism (Johnston et al. 2000). This self-regulated
nature of pegﬁlgrastim ensures a sustained serum concen-
tration of pegﬁlgrastim during the period of neutropenia
and allows the administration of a single dose of peg-
ﬁlgrastim per cycle of chemotherapy, in contrast to
the requirement for a daily subcutaneous injection of
ﬁlgrastim (Johnston et al. 2000; Green et al. 2003).
Clinical trials have shown that a single ﬁxed subcuta-
neous dose of pegﬁlgrastim 6 mg or 100 mg/kg is compa-
rable in safety and efﬁcacy to daily injections of ﬁlgrastim
for reducing the duration of severe CIN following myelo-
suppressive chemotherapy in patients with cancer
(Holmes et al. 2002a,b; Green et al. 2003).
The introduction of pegﬁlgrastim into clinical use in
Spain in 2003 may have had an impact on the pattern of
use of daily G-CSFs – whether used for prophylaxis or for
treatment – and the CIN-related outcomes of chemo-
therapy patients. Here, we report the results of a Spanish
study that compared the usage patterns of daily G-CSF and
pegﬁlgrastim, and the respective outcomes in adults with
non-myeloid malignancies receiving myelosuppressive
chemotherapy.
PATIENTS AND METHODS
The LEARN Study was a multi-centre, retrospective,
observational study of patients with non-myeloid
tumours who underwent cytotoxic chemotherapy sup-
ported by G-CSF treatment. Consecutive medical records
from patients with documented treatment with either
daily G-CSF or pegﬁlgrastim over the same time period
were obtained from 10 Spanish centres during 2003. The
study was approved by the Ethics Committees at all par-
ticipating centres.
From the medical records obtained, the following data
were recorded for each patient on standard data collection
forms: demographic details; diagnosis and classiﬁcation
of their cancer; previous radiotherapy and chemo-
therapy treatment; current radiotherapy and chemo-
therapy treatment; haematological toxicity associated
with chemotherapy (neutropenia); usage pattern of G-CSF
[proactive (primary prophylaxis) versus reactive (second-
ary prophylaxis/treatment) ]; and the incidence of bone
pain and other adverse effects relating to the G-CSF used.
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patients with proactive versus reactive use of G-CSFs; the
duration of treatment with daily G-CSF; and the incidence
of CIN-related outcomes. The CIN-related outcomes
measured were: delay or reduction in dose (>3 days delay
with respect to planned date of administration; <85% of
planned dose administered); incidence of FN; incidence
of hospitalization; and antibiotic use (type, dose and
duration).
Statistical analysis was descriptive in nature. Categori-
cal end points are summarized by the number and per-
centage of individuals in each category. Continuous end
points are summarized by means and standard deviations.
Two-sided 95% conﬁdence intervals are presented where
appropriate.
RESULTS
Baseline characteristics
Records from a total of 248 patients with documented
pegﬁlgrastim or daily G-CSF use during their chemo-
therapy were included in the study. A total of 75 (30%)
patients received pegﬁlgrastim only, and 111 (45%)
patients received daily G-CSF only (99 received ﬁlgrastim
and 12 received lenograstim). A total of 62 (25%) patients
received both daily G-CSF and pegﬁlgrastim. These
patients were treated in the immediate period following
the introduction of pegﬁlgrastim in Spain when physi-
cians were unfamiliar with using a long-acting G-CSF.
Due to the heterogeneity of their management, these 62
patients were excluded from analyses of G-CSF usage and
chemotherapy-related complications.
The demographic characteristics and cancer diagnoses
of the patients included in the study are shown in Table 1.
There were no observed differences in demographic
characteristics between the treatment groups. Overall, the
most common tumour types were lung (25% of all
patients), breast (20%) and malignant lymphomas (20%).
The previous chemotherapy and radiotherapy treat-
ments of patients included in the study are shown in
Table 2. The majority of patients in each treatment group
had previously received ﬁrst-line chemotherapy or were
currently receiving ﬁrst-line chemotherapy. Current che-
motherapy regimens for the most common tumour types
(breast, lung, non-Hodgkin’s lymphoma, Hodgkin’s lym-
phoma and myeloma) are shown in Table 3.
Pattern of G-CSF use
The median number of cycles of chemotherapy per
patient was the same in both the daily G-CSF- and
pegﬁlgrastim-treated patients [4 (range 1–13); 4 (range
1–16) respectively]. Similarly, the median number of
cycles of chemotherapy in which patients received
G-CSF was also the same in both the daily G-CSF- and
pegﬁlgrastim-treated patients [2 (range 1–8); 2 (range 1–7)
respectively].
The pattern of G-CSF use among the patients in the
study is shown in Table 4. The percentage of patients
receiving primary or secondary prophylaxis was compa-
rable between the pegﬁlgrastim and daily G-CSF groups.
However, a potential trend was observed towards less fre-
quent use as treatment in the pegﬁlgrastim group (17%)
compared with the daily G-CSF group (30%).
In the daily G-CSF group, the median number of injec-
tions per cycle was comparable, irrespective of whether
Table 1. The demographic characteristics and most common
tumour diagnoses of patients included in the LEARN study
Demographic
characteristic
Daily G-CSF
(n = 111)
Pegﬁlgrastim
(n = 75)
Both
(n = 62)
Male [n (%)] 60 (54.1) 28 (37.3) 30 (48.4)
Female [n (%)] 51 (45.9) 47 (62.7) 32 (51.6)
Age (years)
(mean  SD)
55.4  14.5 57.0  14.8 59.3  15.6
Weight (kg)
(mean  SD)
71.7  13.8 67.0  13.3 68.3  10.9
Tumour type [n (%)]
Breast 18 (16.2) 20 (26.7) 12 (19.4)
Lung 30 (27.0) 17 (22.7) 16 (25.8)
Non-Hodgkin’s
lymphoma
15 (13.5) 7 (9.3) 14 (22.6)
Hodgkin’s
lymphoma
7 (6.3) 1 (1.3) 6 (9.7)
Multiple myeloma 3 (2.7) 6 (8.0) 1 (1.6)
Gastrointestinal 14 (12.6) 3 (4.0) 6 (9.7)
Gynaecological 8 (7.2) 10 (13.3) 2 (3.2)
Other 16 (14.4) 11 (14.7) 5 (8.1)
G-CSF, granulocyte colony-stimulating factor; SD, standard
deviation.
Table 2. Previous and current chemotherapy and radiotherapy
treatments of patients included in the LEARN study
Daily G-CSF
(n = 111)
Pegﬁlgrastim
(n = 75)
Both
(n = 62)
Previous treatment [n (%)]
Previous chemotherapy
1st line 24 (21.6) 24 (32.0) 4 (6.5)
2 lines 9 (8.1) 13 (17.3) 6 (9.7)
Previous radiotherapy 19 (17.1) 20 (26.7) 4 (6.5)
Current treatment [n (%)]
Current chemotherapy
1st line 90 (81.1) 54 (72.0) 48 (77.4)
2 lines 20 (18.0) 21 (28.0) 14 (22.6)
Missing 1 (0.9)
Current radiotherapy 27 (24.3) 14 (18.7) 14 (22.6)
G-CSF, granulocyte colony-stimulating factor.
ALMENAR et al.
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd
282daily G-CSF was used as primary prophylaxis (6 injections;
range 1–13), secondary prophylaxis (5 injections; range
1–11) or treatment (5 injections; range 1–11).
CIN-related complications
The incidence of chemotherapy-related complications in
cancer patients receiving either pegﬁlgrastim or daily
G-CSF is shown in Table 5. Patients who were treated
with pegﬁlgrastim appeared to have a numerically lower
incidence of dose reduction due to neutropenia, FN, hos-
pitalization due to FN and antibiotic administration than
those who received daily G-CSF. However, due to the
descriptive nature of the analysis in this study, a conclu-
sion of the signiﬁcance cannot be made.
Adverse reactions due to G-CSF therapy
A low incidence of adverse reactions considered by the
investigator to be due to G-CSF treatment was observed.
Three patients (2.7%) in the daily G-CSF group experi-
enced bone pain compared with one (1.3%) in the
pegﬁlgrastim-treated group. Treatment-related adverse
reactions other than pain were reported in six patients
(5.4%) and one patient (1.3%) respectively.
DISCUSSION
In this study of everyday clinical practice in Spain, use of
daily G-CSFs and pegﬁlgrastim followed a similar pattern
with respect to primary and secondary prophylaxis, but
there was a potential trend towards less frequent use of
Table 3. Current chemotherapy regimens administered to patients with the most common tumour types
Tumour type Current chemotherapy treatment
Daily G-CSF
[n (%)]
Pegﬁlgrastim
[n (%)]
Both
[n (%)]
Breast 18 20 12
Anthracycline-based combination regimens 4 (22.2) 13 (65.0) 8 (66.7)
Taxane-based combination regimens 11 (61.1) 4 (20.0) 4 (33.3)
CMF 1 (5.6) 0 (0) 0 (0)
Others 2 (11.1) 3 (15.0) 0 (0)
Lung 30 17 16
Platinum-based combination regimens 18 (60.0) 14 (82.4) 10 (62.5)
Platin + etoposide 8 (26.7) 11 (64.7) 4 (25.0)
Platin + gemcitabine 4 (13.3) 2 (11.8) 3 (18.8)
Platin + vinorelbine 4 (13.3) 0 (0) 3 (18.8)
Platin–taxane combination regimens 6 (20.0) 0 (0) 4 (25.0)
Taxane-based combination regimens 5 (16.7) 1 (5.9) 1 (6.3)
Others 1 (3.3) 2 (11.8) 1 (6.3)
Non-Hodgkin’s lymphoma 15 7 14
CHOP 14 + rituximab 4 (26.7) 2 (28.6) 2 (14.3)
CHOP 21 + rituximab 5 (33.3) 1 (14.3) 6 (42.9)
Others 6 (40.0) 4 (57.1) 6 (42.9)
Hodgkin’s lymphoma 7 1 6
ABVD 6 (85.7) 1 (100.0) 3 (50.0)
Others 1 (14.3) 0 (0) 3 (50.0)
Myeloma 361
VBMCP/VBAD 2 (66.7) 2 (33.3) 0 (0)
Melphalan + prednisolone 1 (33.3) 3 (50.0) 0 (0)
Others 0 1 (16.7) 1 (100.0)
CHOP, cyclophosphamide, doxorubicin, prednisolone, vincristine; CHOP-14, CHOP given on a 14-day cycle; CHOP-21, CHOP given
on a 21-day cycle; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; VBMCP, vincristine, carmustine, melphalan,
cyclophosphamide, prednisolone; VBAD, vincristine carmustine, doxorubicin, dexamethasone; G-CSF, granulocyte colony-stimulating
factor; CMF, cyclophosphamide, methotrexate, ﬂuorouracil.
Table 4. The patterns of use of pegﬁlgrastim or daily G-CSF in cancer patients receiving myelosuppressive chemotherapy
G-CSF usage Daily G-CSF (n = 111) Pegﬁlgrastim (n = 75)
Primary prophylaxis [n (%)] 44 (39.6) 29 (38.7)
Median number of injections per cycle (Minimum, maximum) 6 (1, 13) 1 (1, 3)
Secondary prophylaxis [n (%)] 53 (47.8) 36 (48.0)
Median number of injections per cycle (Minimum, maximum) 5 (1, 11) 1 (1, 1)
Treatment [n (%)] 33 (29.7) 13 (17.3)
Median number of injections per cycle (Minimum, maximum) 5 (1, 11) 1 (1, 1)
G-CSF, granulocyte colony-stimulating factor.
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283pegﬁlgrastim as treatment for FN or CIN. Chemotherapy-
induced neutropenia-related complications, including FN,
appeared to be less frequent in patients receiving peg-
ﬁlgrastim than in those receiving daily G-CSFs.
Granulocyte colony-stimulating factor prophylaxis
reduces the risk of developing CIN, thereby reducing asso-
ciated morbidity and mortality. Reducing CIN also has
the potential to reduce hospitalization and treatment
costs, as well as reducing the requirement for dose reduc-
tions or treatment delays, which may themselves compro-
mise clinical outcomes (Aapro et al. 2006; Smith et al.
2006). As previously mentioned, new guidelines on the
use of G-CSFs recommend primary prophylaxis from the
ﬁrst cycle of chemotherapy for all patients with an overall
risk of developing FN of 20% or higher (Aapro et al. 2006;
Smith et al. 2006). Secondary G-CSF prophylaxis may be
given to patients who have had a prior episode of FN in
order to prevent subsequent neutropenic complications.
As indicated by the new guidelines, the efﬁcacy of pro-
phylactic G-CSFs for reducing the incidence, duration
and intensity of neutropenia is well established with a
variety of chemotherapeutic regimens and tumour types
(Crawford et al. 1991, 2005; Trillet-Lenoir et al. 1993;
Green et al. 2003; Lyman 2005). Data from individual
randomized clinical trials (RCTs) have been supported by
results from meta-analyses, which have also demon-
strated that G-CSF use reduces the incidence and duration
of FN-related hospitalization (Holmes et al. 2002b), as
well as the need for antibiotic treatment and the risk of
infection-related mortality (Kuderer et al. 2007).
In the largest double-blind, randomized, placebo-
controlled multi-centre study of prophylactic peg-
ﬁlgrastim support reported to date, women with breast
cancer receiving docetaxel chemotherapy (a regimen
associated with an expected FN incidence of 20%) were
randomized to receive either placebo (n = 465) or
pegﬁlgrastim (n = 463) administered 24 h after chemo-
therapy (Vogel et al. 2005). The placebo group had an
overall incidence of FN of 17% compared with 1% in the
pegﬁlgrastim group. In addition, in the pegﬁlgrastim and
placebo groups, respectively, the incidence of hospitaliza-
tion was 1% versus 14%, and the use of intravenous
antibiotics was 10% versus 2% (P < 0.001 in each case).
Several large comparative RCTs have demonstrated the
equivalent efﬁcacy and safety of pegﬁlgrastim and
ﬁlgrastim. In two pivotal trials with a similar design, a
single ﬁxed dose of pegﬁlgrastim [6 mg (n = 77) or
100 mg/kg (n = 149) ] was compared with daily ﬁlgrastim
(5 mg/kg/day; n = 222) as prophylactic G-CSF support in a
total of 467 women with breast cancer receiving doxoru-
bicin and docetaxel chemotherapy. The incidences of FN
with ﬁlgrastim were 20 and 18% in the two studies com-
pared with 13 and 9% for patients receiving pegﬁlgrastim
(Holmes et al. 2002a; Green et al. 2003). Indeed, the
pooling of data from these two trials in a combined analy-
sis suggests that the risk of FN was signiﬁcantly lower
for pegﬁlgrastim compared with ﬁlgrastim (relative
risk = 0.56) (Siena et al. 2003).
Clinical studies in patients with solid tumours and lym-
phomas have shown that a median of 11 injections of daily
ﬁlgrastim per cycle is required to achieve a reduction in
the incidence of grade 4 neutropenia equivalent to that
associated with a single injection of pegﬁlgrastim (Holmes
et al. 2002a; Green et al. 2003; Siena et al. 2003; Vose
et al. 2003). A median of 16 injections may be required in
patients with acute myeloid leukaemia (Bosi et al. 2004;
Sierra et al. 2008). In clinical practice, however, there is a
tendency to reduce the number of days of G-CSF given per
cycle (e.g. to 5 or 6 days). The timing and duration of
G-CSF administration following chemotherapy has sig-
niﬁcant effects on haematological recovery and on the
incidence of infections. Studies have shown that FN and
infections are more likely to occur during chemotherapy
cycles that use a reduced number of days of G-CSF
prophylaxis (Crawford et al. 1997; Koumakis et al. 1999;
Kloess et al. 2003; Mucenski & Shogan 2003; Scott et al.
2003). For example, in an analysis of data from a large
breast cancer study, pegﬁlgrastim was compared with
current practice use of G-CSF on days 5–10 of each cycle.
The incidence of FN was 7% among patients receiving
Table 5. The incidence of chemotherapy-related complications in cancer patients receiving either pegﬁlgrastim or daily G-CSF
Chemotherapy-related complications
[n, % of patients (95% CI) ] Daily G-CSF (n = 111) Pegﬁlgrastim (n = 75)
Dose delay 51, 46.0 (36.0; 55.0) 33, 44.0 (33.0; 55.0)
Dose reduction 23, 20.7 (14.2; 29.2) 11, 14.7 (8.2; 24.6)
Dose reduction due to neutropenia 23, 20.7 (14.1; 29.2) 5, 6.7 (2.5; 15.0)
Febrile neutropenia 27, 24.3 (17.2; 33.1) 8, 10.7 (5.3; 19.9)
Hospitalization due to febrile neutropenia 22, 19.8 (13.4; 28.3) 7, 9.3 (4.3; 18.3)
Antibiotic consumption due to febrile neutropenia 19, 17.1 (11.2; 25.3) 6, 8.0 (3.4; 16.7)
CI, conﬁdence interval; G-CSF, granulocyte colony-stimulating factor.
ALMENAR et al.
© 2008 The Authors
Journal compilation © 2008 Blackwell Publishing Ltd
284pegﬁlgrastim compared with 18% for current practice
G-CSF use (Von Minckwitz et al. 2008). In the present
LEARN study, the median number of injections of G-CSF
per cycle was also 5–6. Here, too, there was an indication
of superior protection from CIN with pegﬁlgrastim than
with current practice G-CSF use; however, as this was a
non-randomized study, this ﬁnding must be interpreted
with caution.
In addition to its beneﬁcial impact on health outcomes,
data suggest that pegﬁlgrastim is a cost-effective treat-
ment. Based on the ﬁndings of pivotal trials, a health
economic model from Spain has shown that primary pro-
phylaxis with pegﬁlgrastim was more cost-effective than
11 days of ﬁlgrastim treatment in breast cancer patients
(Mayordomo et al. 2006).
The trend in the current study towards less frequent use
of pegﬁlgrastim as treatment for CIN is unsurprising since
physicians were likely to prefer the ﬂexibility of daily
dosing in this setting, especially if FN occurred late in the
cycle when use of a long-acting dose of pegﬁlgrastim
would potentially overlap with a subsequent chemo-
therapy cycle. In any case, the routine therapeutic use of
G-CSFs is not recommended (Aapro et al. 2006).
In summary, LEARN is the ﬁrst study to compare pat-
terns of pegﬁlgrastim and G-CSF use in clinical practice in
Spain. Our data reveal that soon after its introduction,
pegﬁlgrastim was being administered as primary and sec-
ondary prophylaxis in similar proportions of patients and
in similar numbers of cycles to daily G-CSF when used for
this purpose. As expected, uptake of pegﬁlgrastim for the
treatment of neutropenia was less marked. Importantly,
this study indicates that daily G-CSF prophylaxis was
given for only around 5–6 days per cycle in many patients,
possibly compromising protection against CIN and related
events. Our ﬁndings support those of other authors, sug-
gesting that pegﬁlgrastim given once per cycle may be
more efﬁcacious than daily G-CSF administered according
to current practice. Such ﬁndings would need to be con-
ﬁrmed in further, prospective studies.
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